LONG MINI-FUTURE - NOVO-NORDISK B | Real-time Bid/Ask 12:43:34 13/05/2024 BST | ||
| 21.79 EUR / 21.8 EUR | +3.20% |
|
| Current month | -0.33% | ||
| 1 month | +1.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/05/24 | 21.8 | +3.22% | 0 |
| 08/05/24 | 21.12 | +3.33% | 0 |
| 07/05/24 | 20.44 | +0.44% | 0 |
| 06/05/24 | 20.35 | 0.00% | 0 |
| 03/05/24 | 20.35 | -6.69% | 0 |
Delayed Quote Börse Stuttgart
Last update May 13, 2024 at 08:45 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VN5PF9 |
| ISIN | DE000VN5PF96 |
| Date issued | 21/11/2016 |
| Strike | 90.97 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.43 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.21 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.01 € |
| Spread % | 0.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
- Stock Market
- Certificates
- Certificat
